KRAS and cancer: As described earlier, inhibition of the oncogene‐driven signalling pathways such as KRAS, MEK1/PI3K‐mTOR, BRAF, hexokinase 2 and BCR‐ABL in various cancers can restore OXPHOS and select for tumour cells responsible for relapse of the disease 31, 50, 51, 52.